Top of the morning to you, and a fine one, it is. Yes, we are feeling cheery today, thanks to sunny skies and moderating temperatures enveloping the Pharmalot campus. Moreover, the view from our window offers us a look at a cornucopia of fluttering leaves and colorful trees. A nice way to start the day. So to celebrate, we are brewing cups of stimulation — we are stuck on maple pecan, for those who track this sort of thing — and invite you to join us. While you consider what to do, here are some tidbits. Hope your day is successful and, of course, do keep in touch.

A new report examining the first decade of study results reported on finds there has been slow progress among drug makers and academic research centers in reporting the results of human studies, but the quality of the data may still pose a larger problem, STAT says. When the database was expanded through federal law in 2008 to accommodate clinical trial results, an average of two trials per week posted results, even though 79 trials were completed every week. In 2018, 68 trials with results were posted out of 135 completed trials.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy